Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

30.58
+0.23500.77%
Volume:474.85K
Turnover:14.44M
Market Cap:3.89B
PE:-7.91
High:30.89
Open:30.50
Low:29.38
Close:30.34
52wk High:31.74
52wk Low:10.07
Shares:127.33M
Float Shares:89.84M
Volume Ratio:0.77
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:8.39
PE(LYR):-9.29

Loading ...

Earnings Flash (RCUS) Arcus Biosciences Posts Q1 EPS -$1.02, vs. FactSet Est of -$0.88

MT Newswires Live
·
May 06

Stock Track | Arcus Biosciences Plunges 5.49% After-Hours on Disappointing Q1 Earnings Miss

Stock Track
·
May 06

Arcus Biosciences Q1 EPS $(1.02) Misses $(0.93) Estimate, Sales $17.000M Miss $29.484M Estimate

Benzinga Earnings
·
May 06

Arcus Q1 net loss widens to $128 million; revenue falls to $17 million

Reuters
·
May 06

BRIEF-Arcus Biosciences Q1 Net Income USD -128 Million

Reuters
·
May 06

Arcus Biosciences Q1 Revenue USD 17 Million VS. Ibes Estimate USD 29.5 Million

THOMSON REUTERS
·
May 06

Arcus Biosciences Q1 Pretax Profit USD -128 Million

THOMSON REUTERS
·
May 06

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?

Simply Wall St.
·
May 04

Earning Preview: Arcus Biosciences Inc. this quarter’s revenue is expected to decrease by 19.31%, and institutional views are bullish

Earnings Agent
·
Apr 28

Assessing Arcus Biosciences (RCUS) Valuation After STAR-121 Termination And Gilead Option Changes

Simply Wall St.
·
Apr 27

Arcus Biosciences grants new hire options for 4,200 shares, RSUs for 2,100 shares

Reuters
·
Apr 25

Arcus Biosciences rises 12.2%

TIPRANKS
·
Apr 22

Arcus Biosciences schedules conference call on quarterly results, pipeline update

Reuters
·
Apr 22

Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says

MT Newswires Live
·
Apr 22

Merck setback has positives and negatives for Arcus Biosciences, says BofA

TIPRANKS
·
Apr 22

Merck study miss not a read for Arcus, says H.C. Wainwright

TIPRANKS
·
Apr 22

Analysts’ Top Healthcare Picks: Arcus Biosciences (RCUS), Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
Apr 21

Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs

TIPRANKS
·
Apr 21

U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis

Reuters
·
Apr 21

Arcus Biosciences Discontinues Lung Cancer Trial With Gilead

Dow Jones
·
Apr 20